A phase 1 study of teclistamab, a humanized B-cell maturation antigen (BCMA) × CD3 bispecific antibody, for the treatment of relapsed and/or refractory multiple myeloma (rrMM) - Mateos, M V; Usmani, S Z; Nahi, H
EHA 2020; abstract S206